Loss of function of FIGNL1, a DNA damage response gene, causes human ovarian dysgenesis.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
01 Sep 2023
Historique:
received: 19 01 2023
revised: 18 05 2023
accepted: 14 08 2023
medline: 25 9 2023
pubmed: 23 9 2023
entrez: 23 9 2023
Statut: ppublish

Résumé

Ovarian dysgenesis (OD), an XX disorder of sex development, presents with primary amenorrhea, hypergonadotrophic hypogonadism, and infertility. In an Ashkenazi Jewish patient with OD, whole exome sequencing identified compound heterozygous frameshifts in FIGNL1, a DNA damage response (DDR) gene: c.189del and c.1519_1523del. Chromosomal breakage was significantly increased in patient cells, both spontaneously, and following mitomycin C exposure. Transfection of DYK-tagged FIGNL1 constructs in HEK293 cells showed no detectable protein in FIGNL1c.189del and truncation with reduced expression in FIGNL1c.1519_1523del (64% of wild-type [WT], P = .003). FIGNL1 forms nuclear foci increased by phleomycin treatment (20.6 ± 1.6 vs 14.8 ± 2.4, P = .02). However, mutant constructs showed reduced DYK-FIGNL1 foci formation in non-treated cells (0.8 ± 0.9 and 5.6 ± 1.5 vs 14.8 ± 2.4 in DYK-FIGNL1WT, P < .001) and no increase with phleomycin treatment. In conclusion, FIGNL1 loss of function is a newly characterized OD gene, highlighting the DDR pathway's role in ovarian development and maintenance and suggesting chromosomal breakage as an assessment tool in XX-DSD patients.

Identifiants

pubmed: 37740949
pii: 7280340
doi: 10.1093/ejendo/lvad127
doi:

Substances chimiques

ATPases Associated with Diverse Cellular Activities EC 3.6.4.-
FIGNL1 protein, human EC 3.6.4.-
Microtubule-Associated Proteins 0
Nuclear Proteins 0
Phleomycins 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

K7-K14

Subventions

Organisme : Israel Science Foundation
ID : IPMP 3797/21
Organisme : Koum Foundation
Organisme : MOJ Estate Committee Fund
ID : 20200808

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Natan Florsheim (N)

Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Division of Pediatric Endocrinology, Hadassah Medical Center, Jerusalem, Israel.

Larisa Naugolni (L)

Pediatric Endocrinology and Diabetes Institute, Shamir Medical Center, Zerifin, Israel.

Fouad Zahdeh (F)

Translational Genomics Lab, Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.

Orit Lobel (O)

Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.

Batel Terespolsky (B)

Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Rachel Michaelson-Cohen (R)

Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel.

Merav Y Gold (MY)

The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.

Michal Goldberg (M)

The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.

Paul Renbaum (P)

Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.

Ephrat Levy-Lahad (E)

Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

David Zangen (D)

Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Division of Pediatric Endocrinology, Hadassah Medical Center, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH